Incyte Corporation (INCY) Free Cash Flow Yield: 7.14%
Is Incyte Corporation’s free cash flow yield high or low?
Incyte Corporation's free cash flow yield of 7.14% is 76% above its 5-year average of 4.07%, near the high end of its 5-year range (0.10%–7.60%).
As of Sunday, June 21, 2026. 14.51% above its 12-month average of 6.24%.
INCY Free Cash Flow Yield Chart
INCY Average Free Cash Flow Yield Chart
INCY Current vs Average Free Cash Flow Yield Chart
INCY Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
7.14%
FREE CASH FLOW YIELD AVG TTM
6.24%
FREE CASH FLOW YIELD AVG 3Y
4.27%
FREE CASH FLOW YIELD AVG 5Y
4.07%
FREE CASH FLOW YIELD AVG 10Y
3.18%
FREE CASH FLOW YIELD AVG 15Y
2.74%
FREE CASH FLOW YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
+14.51%
CURRENT VS 3Y AVG
+67.04%
CURRENT VS 5Y AVG
+75.59%
CURRENT VS 10Y AVG
+124.80%
CURRENT VS 15Y AVG
+160.36%
CURRENT VS 20Y AVG
N/A
INCY Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 7.14% | 6.24% | 4.27% | 4.07% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 6.53% | 5.80% | 5.23% | 7.17% |
| Viatris Inc. (VTRS)vs › | $17.90B | 9.46% | 12.46% | 14.77% | 16.03% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 10.66% | 8.74% | 6.11% | 5.51% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 5.82% | 6.28% | 5.68% | 7.87% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 4.01% | 5.22% | 5.78% | 5.82% |
| BioNTech SE (BNTX)vs › | $22.98B | 6.51% | 4.03% | 18.59% | 19.71% |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | 3.42% | 3.21% | 3.25% | 2.88% |
| Waters Corporation (WAT)vs › | $23.17B | 0.90% | 2.78% | 2.66% | 2.69% |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 6.46% | 3.67% | 3.12% | 2.77% |
Yield Comparison
FCF Yield
7.14%
Earnings Yield
7.21%
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
Incyte Corporation Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation Free Cash Flow Yield FAQ
- What is the free cash flow yield for Incyte Corporation (INCY)?
- The free cash flow yield for INCY stock is 7.14%.
- Is Incyte Corporation's free cash flow yield high or low?
- Incyte Corporation's free cash flow yield of 7.14% is 76% above its 5-year average of 4.07%, near the high end of its 5-year range (0.10%–7.60%).
- What is the TTM average free cash flow yield for Incyte Corporation (INCY)?
- The TTM average free cash flow yield for INCY stock is 6.24%.
- What is the 3Y average free cash flow yield for Incyte Corporation (INCY)?
- The 3Y average free cash flow yield for INCY stock is 4.27%.
- What is the 5Y average free cash flow yield for Incyte Corporation (INCY)?
- The 5Y average free cash flow yield for INCY stock is 4.07%.
- What is the 10Y average free cash flow yield for Incyte Corporation (INCY)?
- The 10Y average free cash flow yield for INCY stock is 3.18%.
- What is the 15Y average free cash flow yield for Incyte Corporation (INCY)?
- The 15Y average free cash flow yield for INCY stock is 2.74%.
Incyte Corporation Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-18 | 7.14% |
| 2026-06-17 | 7.09% |
| 2026-06-16 | 7.03% |
| 2026-06-15 | 6.88% |
| 2026-06-12 | 6.46% |
| 2026-06-11 | 6.51% |
| 2026-06-10 | 6.66% |
| 2026-06-09 | 6.79% |
| 2026-06-08 | 6.97% |
| 2026-06-05 | 6.85% |
| 2026-06-04 | 6.93% |
| 2026-06-03 | 7.16% |
| 2026-06-02 | 7.60% |
| 2026-06-01 | 7.34% |
| 2026-05-29 | 7.25% |
| 2026-05-28 | 7.19% |
| 2026-05-27 | 7.20% |
| 2026-05-26 | 7.23% |
| 2026-05-22 | 7.22% |
| 2026-05-21 | 7.20% |
| 2026-05-20 | 7.23% |
| 2026-05-19 | 7.34% |
| 2026-05-18 | 7.37% |
| 2026-05-15 | 7.36% |
| 2026-05-14 | 7.18% |
| 2026-05-13 | 7.10% |
| 2026-05-12 | 7.08% |
| 2026-05-11 | 6.99% |
| 2026-05-08 | 7.12% |
| 2026-05-07 | 7.17% |
| 2026-05-06 | 7.03% |
| 2026-05-05 | 7.20% |
| 2026-05-04 | 7.22% |
| 2026-05-01 | 7.24% |
| 2026-04-30 | 7.36% |
| 2026-04-29 | 7.08% |
| 2026-04-28 | 7.18% |
| 2026-04-27 | 6.91% |
| 2026-04-24 | 6.99% |
| 2026-04-23 | 6.93% |
| 2026-04-22 | 6.84% |
| 2026-04-21 | 6.88% |
| 2026-04-20 | 6.83% |
| 2026-04-17 | 6.76% |
| 2026-04-16 | 6.94% |
| 2026-04-15 | 6.81% |
| 2026-04-14 | 6.77% |
| 2026-04-13 | 6.93% |
| 2026-04-10 | 6.89% |
| 2026-04-09 | 6.82% |
| 2026-04-08 | 6.90% |
| 2026-04-07 | 7.06% |
| 2026-04-06 | 6.97% |
| 2026-04-02 | 6.90% |
| 2026-04-01 | 7.02% |
| 2026-03-31 | 7.03% |
| 2026-03-30 | 7.33% |
| 2026-03-27 | 7.33% |
| 2026-03-26 | 7.17% |
| 2026-03-25 | 7.17% |
| 2026-03-24 | 7.30% |
| 2026-03-23 | 7.32% |
| 2026-03-20 | 7.29% |
| 2026-03-19 | 7.12% |
| 2026-03-18 | 7.17% |
| 2026-03-17 | 7.02% |
| 2026-03-16 | 7.11% |
| 2026-03-13 | 7.15% |
| 2026-03-12 | 7.19% |
| 2026-03-11 | 6.99% |
| 2026-03-10 | 6.89% |
| 2026-03-09 | 6.81% |
| 2026-03-06 | 6.90% |
| 2026-03-05 | 6.80% |
| 2026-03-04 | 6.69% |
| 2026-03-03 | 6.75% |
| 2026-03-02 | 6.61% |
| 2026-02-27 | 6.53% |
| 2026-02-26 | 6.61% |
| 2026-02-25 | 6.62% |
| 2026-02-24 | 6.55% |
| 2026-02-23 | 6.56% |
| 2026-02-20 | 6.53% |
| 2026-02-19 | 6.50% |
| 2026-02-18 | 6.42% |
| 2026-02-17 | 6.54% |
| 2026-02-13 | 6.54% |
| 2026-02-12 | 6.57% |
| 2026-02-11 | 6.69% |
| 2026-02-10 | 6.61% |
| 2026-02-09 | 5.45% |
| 2026-02-06 | 5.48% |
| 2026-02-05 | 5.78% |
| 2026-02-04 | 5.79% |
| 2026-02-03 | 5.89% |
| 2026-02-02 | 5.79% |
| 2026-01-30 | 5.94% |
| 2026-01-29 | 5.88% |
| 2026-01-28 | 5.87% |
| 2026-01-27 | 5.74% |
| 2026-01-26 | 5.79% |
| 2026-01-23 | 5.83% |
| 2026-01-22 | 5.66% |
| 2026-01-21 | 5.68% |
| 2026-01-20 | 5.79% |
| 2026-01-16 | 5.60% |
| 2026-01-15 | 5.65% |
| 2026-01-14 | 5.61% |
| 2026-01-13 | 5.75% |
| 2026-01-12 | 5.59% |
| 2026-01-09 | 5.56% |
| 2026-01-08 | 5.61% |
| 2026-01-07 | 5.37% |
| 2026-01-06 | 5.57% |
| 2026-01-05 | 5.84% |
| 2026-01-02 | 5.86% |
| 2025-12-31 | 6.02% |
| 2025-12-30 | 6.01% |
| 2025-12-29 | 5.98% |
| 2025-12-26 | 5.93% |
| 2025-12-24 | 5.92% |
| 2025-12-23 | 5.89% |
| 2025-12-22 | 5.90% |
| 2025-12-19 | 5.79% |
| 2025-12-18 | 6.11% |
| 2025-12-17 | 6.09% |
| 2025-12-16 | 6.12% |
| 2025-12-15 | 6.02% |
| 2025-12-12 | 6.23% |
| 2025-12-11 | 6.18% |
| 2025-12-10 | 6.25% |
| 2025-12-09 | 6.25% |
| 2025-12-08 | 6.15% |
| 2025-12-05 | 5.80% |
| 2025-12-04 | 5.92% |
| 2025-12-03 | 5.85% |
| 2025-12-02 | 5.86% |
| 2025-12-01 | 5.82% |
| 2025-11-28 | 5.69% |
| 2025-11-26 | 5.62% |
| 2025-11-25 | 5.63% |
| 2025-11-24 | 5.59% |
| 2025-11-21 | 5.82% |
| 2025-11-20 | 5.84% |
| 2025-11-19 | 5.87% |
| 2025-11-18 | 5.72% |
| 2025-11-17 | 5.70% |
| 2025-11-14 | 5.70% |
| 2025-11-13 | 5.64% |
| 2025-11-12 | 5.49% |
| 2025-11-11 | 5.49% |
| 2025-11-10 | 5.61% |
| 2025-11-07 | 5.61% |
| 2025-11-06 | 5.65% |
| 2025-11-05 | 5.62% |
| 2025-11-04 | 5.77% |
| 2025-11-03 | 5.85% |
| 2025-10-31 | 6.36% |
| 2025-10-30 | 6.42% |
| 2025-10-29 | 6.59% |
| 2025-10-28 | 6.49% |
| 2025-10-27 | 5.11% |
| 2025-10-24 | 5.21% |
| 2025-10-23 | 5.33% |
| 2025-10-22 | 5.40% |
| 2025-10-21 | 5.45% |
| 2025-10-20 | 5.52% |
| 2025-10-17 | 5.43% |
| 2025-10-16 | 5.45% |
| 2025-10-15 | 5.40% |
| 2025-10-14 | 5.53% |
| 2025-10-13 | 5.61% |
| 2025-10-10 | 5.68% |
| 2025-10-09 | 5.61% |
| 2025-10-08 | 5.57% |
| 2025-10-07 | 5.46% |
| 2025-10-06 | 5.46% |
| 2025-10-03 | 5.48% |
| 2025-10-02 | 5.52% |
| 2025-10-01 | 5.49% |
| 2025-09-30 | 5.61% |
| 2025-09-29 | 5.67% |
| 2025-09-26 | 5.75% |
| 2025-09-25 | 5.83% |
| 2025-09-24 | 5.65% |
| 2025-09-23 | 5.63% |
| 2025-09-22 | 5.61% |
| 2025-09-19 | 5.50% |
| 2025-09-18 | 5.53% |
| 2025-09-17 | 5.61% |
| 2025-09-16 | 5.67% |
| 2025-09-15 | 5.72% |
| 2025-09-12 | 5.72% |
| 2025-09-11 | 5.52% |
| 2025-09-10 | 5.52% |
| 2025-09-09 | 5.56% |
| 2025-09-08 | 5.50% |
| 2025-09-05 | 5.49% |
| 2025-09-04 | 5.57% |
| 2025-09-03 | 5.47% |
| 2025-09-02 | 5.53% |
| 2025-08-29 | 5.62% |
| 2025-08-28 | 5.69% |
| 2025-08-27 | 5.61% |
| 2025-08-26 | 5.66% |
| 2025-08-25 | 5.61% |
| 2025-08-22 | 5.60% |
| 2025-08-21 | 5.50% |
| 2025-08-20 | 5.52% |
| 2025-08-19 | 5.57% |
| 2025-08-18 | 5.60% |
| 2025-08-15 | 5.47% |
| 2025-08-14 | 5.52% |
| 2025-08-13 | 5.54% |
| 2025-08-12 | 5.83% |
| 2025-08-11 | 6.01% |
| 2025-08-08 | 6.07% |
| 2025-08-07 | 6.08% |
| 2025-08-06 | 6.13% |
| 2025-08-05 | 6.12% |
| 2025-08-04 | 6.10% |
| 2025-08-01 | 6.29% |
| 2025-07-31 | 6.35% |
| 2025-07-30 | 6.13% |
| 2025-07-29 | 6.15% |
| 2025-07-28 | 2.08% |
| 2025-07-25 | 2.08% |
| 2025-07-24 | 2.07% |
| 2025-07-23 | 2.06% |
| 2025-07-22 | 2.12% |
| 2025-07-21 | 2.16% |
| 2025-07-18 | 2.15% |
| 2025-07-17 | 2.11% |
| 2025-07-16 | 2.10% |
| 2025-07-15 | 2.13% |
| 2025-07-14 | 2.08% |
| 2025-07-11 | 2.12% |
| 2025-07-10 | 2.07% |
| 2025-07-09 | 2.12% |
| 2025-07-08 | 2.15% |
| 2025-07-07 | 2.17% |
| 2025-07-03 | 2.13% |
| 2025-07-02 | 2.14% |
| 2025-07-01 | 2.12% |
| 2025-06-30 | 2.14% |
| 2025-06-27 | 2.13% |
| 2025-06-26 | 2.06% |
| 2025-06-25 | 2.16% |
| 2025-06-24 | 2.11% |
| 2025-06-23 | 2.17% |
| 2025-06-20 | 2.13% |
| 2025-06-18 | 2.13% |
| 2025-06-17 | 2.12% |
| 2025-06-16 | 2.05% |
| 2025-06-13 | 2.15% |
| 2025-06-12 | 2.11% |
| 2025-06-11 | 2.12% |
| 2025-06-10 | 2.08% |
| 2025-06-09 | 2.09% |
| 2025-06-06 | 2.12% |
Showing the most recent 260 of 2,515 data points. The chart above shows the full history.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury